Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673868 · ClinicalTrials.gov registry record · Phase 1
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00673868 is a Phase 1 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT00673868, a Phase 1 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Center (DUMC), by measuring levels of CMV DNA and virus specific T cell precursors at intervals post-infusion.
Interventions
- BIOLOGICAL CMV Specific Cytotoxic T Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673868
The ClinicalTrials.gov registry entry for NCT00673868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CMV Specific Cytotoxic T Lymphocytes is the first listed.
NCT00673868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673868 about?
NCT00673868 is a clinical study titled "Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants". This study examines the immunologic and virologic effects of prophylactic CMV specific CTL in recipients of T cell depleted stem cell transplant (TCD SCT) at Duke University Medical Center (DUMC), by measuring levels of CMV DNA and virus specific T cell precursors at intervals post-infusion.
What is the current status of trial NCT00673868?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2007-10. Estimated completion is 2008-08-06.
What interventions are being tested in trial NCT00673868?
The interventions under investigation include: CMV Specific Cytotoxic T Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00673868?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.